Kyowa Kirin is continuing to monitor the COVID-19 outbreak. Learn More

Adverse reactions that may require dose adjustments1

Table of adverse reactions requiring dose adjustments in patients taking Poteligeo

Autoimmune complications

  • In MAVORIC, 2% (6/319) of patients required systemic immunosuppressants for immune-mediated reactions. Grade 1 or 2 new onset hyperthyroidism occurred in 1% of patients. Grade 3 or higher immune-mediated or possibly immune-mediated reactions reported with POTELIGEO include myositis, myocarditis, polymyositis, hepatitis, pneumonitis, and a variant of Guillain-Barré syndrome
  • Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions

For more information on dosing, see the POTELIGEO Dosing and Administration Guide

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

SEE LESS